Alpha Teknova (TKNO) Earnings Date & Reports

Key Takeaways

• Alpha Teknova reported record third quarter 2026 revenue of $12.7 million, up 22% year over year and above the consensus estimate of $11.64 million.
• The net loss narrowed to $3.5 million, or $0.06 per diluted share, better than the $0.07 loss per share analysts expected and the $0.08 loss reported a year earlier.
• Clinical Solutions revenue jumped 86% to $3.2 million, while Lab Essentials revenue rose 9% to $9.0 million.
• Gross margin expanded to 38.0% from 30.7% in the prior-year quarter, driven by higher revenue and favorable cost absorption.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) improved to a loss of roughly $1.0 million.
• Management attributed the momentum to broad-based demand, including a pickup in custom-product orders from small and mid-sized biotech customers.
• For more on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, be sure to explore the additional pages.
• Discover automated trading ideas with Trending AI Robots.

Earnings Context and Why It Matters

Alpha Teknova, a life sciences company that manufactures critical reagents for drug discovery, vaccines, and molecular diagnostics, is in the middle of a multi-year push toward profitability. The third quarter of 2026 marked the company's second consecutive record-revenue quarter, reinforcing the idea that a gradual recovery in biotech funding is translating into renewed demand for its made-to-order products. For investors, the report matters because it tests whether Teknova can sustain double-digit revenue growth, expand margins, and shrink its cash burn while the broader life sciences tools market stabilizes. The results also provide an early read on how effectively the company's stepped-up commercial investments are beginning to convert into order flow.

Reported Results

Alpha Teknova posted total revenue of $12.7 million for the third quarter of 2026, a 22% increase from $10.5 million in the year-ago period and above the $11.64 million analyst estimate. Lab Essentials revenue was $9.0 million, up 9%, while Clinical Solutions revenue surged 86% to $3.2 million. Other revenue was $0.5 million.

Gross profit rose to $4.8 million from $3.2 million, with gross margin improving to 38.0% from 30.7%, helped by higher revenue and favorable fixed-cost absorption. Operating expenses increased to $8.0 million from $7.2 million, reflecting higher sales and marketing spending. The company reported a net loss of $3.5 million, or $0.06 per diluted share, narrowing from a loss of $4.3 million, or $0.08 per share, a year earlier and beating the estimated loss of $0.07 per share. Adjusted EBITDA was a loss of approximately $1.0 million. For the first nine months of 2026, total revenue reached $36.0 million, compared with $30.5 million in the same period of 2025.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking the life sciences tools sector or monitoring names like Alpha Teknova, the AI Screener offers a practical way to surface potential opportunities quickly and systematically.

Market Reaction and Investor Sentiment

Heading into the report, sentiment around Alpha Teknova had been improving, with several analysts raising price targets and initiating or upgrading coverage on the stock amid signs of a biotech funding recovery. The third quarter's top-line beat and narrower-than-expected loss reinforced that narrative, particularly the 86% jump in Clinical Solutions revenue and the broad-based strength management described across life science tools, diagnostics, and biopharma customers. Still, investors continue to weigh the company's persistent GAAP (Generally Accepted Accounting Principles) losses and negative adjusted EBITDA against the progress on margins and cash usage, making the durability of demand a central question for the shares.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should watch whether Teknova can sustain its revenue momentum and keep narrowing losses through the fourth quarter and into 2027. Management has signaled that improvements in biotech funding typically flow through to reagent demand with a lag, suggesting that recent funding trends could support continued order growth in coming quarters.

The mix between Lab Essentials and the faster-growing, higher-ticket Clinical Solutions segment will remain a key margin driver, given the company's high fixed-cost structure and its estimate that each additional revenue dollar drops through at a roughly 70% marginal cash rate. Commercial investments, including the onboarding of new sales associates, are expected to begin contributing more meaningfully by early 2027.

Investors should also monitor gross margin progression, adjusted EBITDA trajectory, and free cash flow, as well as any commentary on reaching positive adjusted EBITDA as revenue scales toward management's stated targets. External factors such as biotech funding cycles, customer concentration, and input-cost pressures remain important variables to track in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations